Ourobio Pitch Deck Teardown: Turning Dairy Waste

Ourobio Pitch Deck Analysis

Ourobio is positioning itself as a key player in the circular bioeconomy, specifically targeting the chemicals and materials industry. This 10-slide deck serves as a high-level introduction to their technology and early-stage traction. It focuses heavily on the 'why' and the 'how' of their bioprocess, while leaving much of the 'how much' (financials and market size) to follow-up conversations.

Slide 1: Title Slide

The deck opens with a clean logo and the tagline: "Catalyzing the circular bioeconomy." The branding is professional and thematic, using blues and greens to signal environmental sustainability. There is no mention of the specific round or date on this slide, though the source listing indicates a late 2022 timeframe.

Slide 2: The Thesis

Slide 2 presents a simple, bold statement: "Biotechnology is the sustainable alternative to petrochemistry." This serves as the foundational belief of the company. It is a high-level industry observation rather than a specific problem statement, which is a common approach in deep-tech decks where the 'problem' (petrochemical pollution) is widely acknowledged by the target investor audience.

Slide 3: The Vision and Tech Overview

Ourobio defines its role as the "chemical and materials industry’s bioeconomy partner." The slide explains that they use industrial byproducts to produce low-footprint, targeted additives. A three-part graphic illustrates the flow: Organic waste from industry goes into Ourobio’s proprietary bioprocesses, resulting in low-footprint, bio-based chemicals and materials. This slide successfully communicates the circularity of their business model.

Slide 4: Our First Product

This is the 'Proof of Concept' slide. Ourobio specifies that their first application turns "dairy waste into low-footprint biodegradable plastic colorant masterbatches." The technical highlight here is the "single fermentation step" used to produce complementary bio-based additives simultaneously. The slide includes a visual of the "Blue Biosynthetic Masterbatches," providing a tangible output for an otherwise abstract biological process.

Slide 5: Traction and Achievements

Slide 5 provides concrete evidence of progress. Key metrics include:

TRL 3/4: Bootstrapped R&D has reached the stage of producing polymers and colorants from whey using an engineered strain. · 1000+ hours of market discovery: This effort yielded MOUs from both upstream and downstream partners, indicating market pull. · IP Status: The technology is patent-pending with a defined patent family and follow-on strategy.

The slide also features a quote from StartUs Insights naming them one of the "5 Top Biomaterials Startups You Should Watch in 2022."

Slide 6: Additional Milestones

This slide details the company's capitalization and operational history:

$400k bootstrapped: This includes an EPA SBIR (Small Business Innovation Research) grant and various competition awards. · $200k raised: Sourced from Heritage Ventures Group and a pre-seed extension on RoundHere. · 15+ successful intern & consulting engagements: Demonstrating organizational growth. · 3+ year-long relationships: Established with VCs and prospective partners.

The mention of the EPA SBIR is a significant validator for a biotech startup, as these grants involve rigorous technical peer review.

Slide 7: Innovation Roadmap

Ourobio outlines its future pipeline, moving from the initial Blue Masterbatches into:

Biodegradable Plastic Blends · Portfolio of PHA co-polymers · Multi-colored Masterbatches · Novel, performance-enhancing additives

This slide is intended to show that Ourobio is a platform company, not just a 'blue dye' company. However, it lacks a timeline or specific milestones for these developments.

Slide 8: The Team

Kobe Rogers (COO): B.S. Chemistry, with 5 years of independent biochemistry R&D experience. · Alec Brewer (CEO): B.S. BME (Biomedical Engineering), with 5+ years of entrepreneurship and small business experience.

The right side of the slide is crowded with logos from accelerators and partners, including Halcyon, Virginia Tech, GC3, D3, EPA, VentureWell, Plug and Play, and MassChallenge. While the logos provide social proof, the slide lacks a deep bench of senior advisors or industry veterans, which is often expected in complex biotech ventures.

Slide 9: The Ask

Pre-seed/Seed Investor Intros · Organic Waste Streams · Corporate Champion(s)

Crucially, it does not state how much money they are currently raising, the valuation, or the specific use of funds. In a formal pitch deck, investors typically expect a clear dollar amount and a breakdown of how that capital will move the company to the next TRL or commercial milestone.

Slide 10: Contact Slide

The deck concludes with contact information for both founders. The design remains consistent with the rest of the deck, maintaining the professional aesthetic.

What Ourobio Does Well

Technical Clarity: The deck does an excellent job of explaining a complex biological process in simple terms. The use of dairy waste (whey) as a specific feedstock makes the abstract concept of 'organic waste' much more relatable and understandable for a generalist investor.

Validation: Mentioning the EPA SBIR grant and the TRL 3/4 status provides necessary technical credibility. The claim of 1000+ hours of market discovery shows that the founders are not just building in a lab but are actively talking to the market.

Visual Storytelling: The graphics on slides 3, 4, and 7 effectively communicate the circular nature of the business and the potential for a broad product platform.

What is Missing from the Deck

Market Sizing: There is no mention of the Total Addressable Market (TAM). Investors need to know if the plastic colorant market or the PHA polymer market is large enough to support a venture-scale return.

Financial Projections: The deck contains no forward-looking financials. There is no indication of when the company expects to reach revenue, what their margins look like, or the cost-competitiveness of their bio-based masterbatches compared to traditional petrochemical alternatives.

Competitive Landscape: Ourobio does not address who else is working in the waste-to-polymer space. A competitive matrix or a 'Why Us' slide comparing their single-step fermentation to multi-step processes would have strengthened the case for their proprietary advantage.

Specific Funding Ask: As noted, slide 9 is too generic. A founder should always specify the amount they are raising and what milestones that money will buy (e.g., "Raising $1.5M to build a pilot plant and achieve TRL 6").

Founder Takeaways

Focus on the 'Platform': Ourobio successfully frames their first product as a proof of concept for a larger platform. Founders of deep-tech companies should follow this lead: show one specific, viable application to prove the tech works, then show the roadmap for how that tech scales into other verticals.

Leverage Non-Dilutive Funding: Highlighting the $400k in bootstrapped/grant funding is a strong signal. It shows that the founders are resourceful and that external government bodies (EPA) have vetted the technology.

Don't Hide the Numbers: While this deck works as a 'teaser,' a full investor deck must include market size and a clear financial ask. If you are asking for 'intros,' you are networking; if you are asking for 'capital,' you need to name the price and the plan.